Alpha Teknova, Inc.

TKNONasdaq· In Vitro & In Vivo Diagnostic Substances

Price History

Revenue

$40.5M

▲ 7.4% YoY

Net Income

-$17.3M

▲ 35.5% YoY

EPS

$-0.32

▲ 43.9% YoY

Cash

$5.9M

▲ 59.4% YoY

FY 2025 · As of 2025-12-31

Pro

10-K Year-over-Year Diff

AI-powered analysis of what changed between the last two annual reports — new risks, removed language, strategy shifts.